IP Library Granted Patent US 9,216,225
Granted Patent B2
US 9,216,225 · App. 13/599,777 · Granted Dec 22, 2015

Remote assembly of targeted nanoparticles using H-phosphate ENE/-YNE hydrophosphonylation reactions

Inventors: Thomas E. Rogers (Ballwin, MO); Kah Tiong Kuan (Ballwin, MO)
Assignee: MALLINCKRODT LLC
A61K47/48084A61K47/48215A61K47/48815
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,216,225
App. No.
13/599,777
Granted
Dec 22, 2015
Kind
B2
Abstract

The present invention provides phosphonate compounds and methods of preparing the phosphonate compounds so as to allow, for example, increased capability to modify nanoparticles for targeted drug delivery applications.

Claims (15)

1. A compound of the formula:

wherein:

the bond identified by is a single or double bond;

each of L 1 , L 2 and L 3 is a bond or a linking group;

each of R 1 and R 2 is an attachment component selected from the group consisting of a C 8 -C 36 alkyl and cholesterol;

R 3 is a stealth agent wherein the stealth agent is selected from the group consisting of: polyalkylene oxide, polyethylene glycol, a dendrimer, polyvinyl alcohol, polycarboxylate, a polysaccharide, and hydroxyalkyl starch; and

R 4 is a member selected from the group consisting of H and —P(═O)(OL 1 -R 1 )(OL 2 -R 2 ), wherein when R 4 is other than H the bond identified by is a single bond.

2. The compound of claim 1 , wherein each of L 1 and L 2 is a bond.

3. The compound of claim 1 , wherein each of L 1 and L 2 is a bond and each of R 1 and R 2 is independently selected from the group consisting of a saturated or unsaturated C 10-24 alkyl group and a substituted saturated or unsaturated C 10-24 alkyl group.

4. The compound of claim 1 , wherein L 3 is a linking group.

5. The compound of claim 4 , wherein R 3 is selected from the group consisting of PEG 500 , PEG 1000 , PEG 2000 , and PEG 5000 .

6. The compound of claim 1 , having the formula:

wherein each of R 1 and R 2 is elected from a saturated or unsaturated C 10-24 alkyl group, a substituted saturated or unsaturated C 10-24 alkyl group, and cholesterol; and each of L 1 and L 2 is a bond.

7. The compound of claim 6 , wherein R 3 is selected from the group consisting of PEG 500 , PEG 1000 , PEG 2000 , and PEG 5000 .

8. The compound of claim 6 , wherein L 3 is a hydrophilic, non-immunogenic, water soluble linking group.

Assignments (3)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2013
From: ROGERS, THOMAS E.; KUAN, KAH TIONG
To: MALLINCKRODT LLC
Reel/Frame 030417/0749 →
Continuity (2)
Provisional Application 61529665 · Aug 31, 2011
Related Publication 20130066098A1 · Mar 14, 2013